Financials data is unavailable for this security.
View more
Year on year Regen BioPharma Inc 's net income fell -52.67% from 2.44m to 1.16m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 127.26% to 300.65%.
Gross margin | -- |
---|---|
Net profit margin | -392.01% |
Operating margin | -165.23% |
Return on assets | -407.33% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, Regen BioPharma Inc increased its cash reserves by 136.41%, or 69.84k. Cash Flow from Financing totalled 243.75k or 103.04% of revenues. In addition the company used 173.92k for operations while cash used for investing totalled .
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.18 |
---|---|
Tangible book value per share | -1.18 |
More ▼
Balance sheet in USDView more
Current ratio | 0.0286 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼